A general genetic approach in Escherichia coli for determining the mechanism(s) of action of tumoricidal agents: application to DMP 840, a tumoricidal agent.
We describe here a simple and easily manipulatable Escherichia coli-based genetic system that permits us to identify bacterial gene products that modulate the sensitivity of bacteria to tumoricidal agents, such as DMP 840, a bisnaphthalimide drug. To the extent that the action of these agents is conserved, these studies may expand our understanding agents is conserved, these studies may expand our understanding of how the agents work in mammalian cells. The approach briefly is to use a library of E. coli genes that are overexpressed in a high copy number vector to select bacterial clones that are resistant to the cytotoxic effects of drugs. AtolC bacterial mutant is used to maximize permeability of cells to hydrophobic organic molecules. By using DMP 840 to model the system, we have identified two genes, designated mdaA and mdaB, that impart resistance to DMP 840 when they are expressed at elevated levels. mdaB maps to E. coli map coordinate 66, is located between the parE and parC genes, and encodes a protein of 22 kDa. mdaA maps to E. coli map coordinate 18, is located adjacent to the glutaredoxin (grx) gene, and encodes a protein of 24 kDa. Specific and regulatable overproduction of both of these proteins correlates with DMP 840 resistance. Overproduction of the MdaB protein also imparts resistance to two mammalian topoisomerase inhibitors, Adriamycin and etoposide. In contrast, overproduction of the MdaA protein produces resistance only to Adriamycin. Based on its drug-resistance properties and its location between genes that encode the two subunits of the bacterial topoisomerase IV, we suggest that mdaB acts by modulating topoisomerase IV activity. The location of the mdaA gene adjacent to grx suggests it acts by a drug detoxification mechanism.
Chatterjee
P K
PK
DuPont Merck Pharmaceutical Company, Glenolden, PA 19036, USA.
Sternberg
N L
NL
D000595:Amino Acid Sequence; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001089:Arabinose / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics; D001483:Base Sequence; D027101:DNA Topoisomerase IV; D004352:Drug Resistance, Microbial / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D004926:Escherichia coli / Q000235:genetics*; D029968:Escherichia coli Proteins; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects; D015723:Gene Library; D005798:Genes, Bacterial; D008658:Inactivation, Metabolic; D007546:Isoquinolines / Q000494:pharmacology*; D008698:Mesylates / Q000494:pharmacology*; D008969:Molecular Sequence Data; D009601:Nitroreductases; D016366:Open Reading Frames / Q000235:genetics; D015183:Restriction Mapping; D017422:Sequence Analysis, DNA; D059005:Topoisomerase II Inhibitors; D018675:Toxicity Tests / Q000379:methods*
D000970:Antineoplastic Agents; D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D007546:Isoquinolines; C095690:MdaB protein, E coli; D008698:Mesylates; D059005:Topoisomerase II Inhibitors; C084899:bisnafide; D001089:Arabinose; C116053:NfsA protein, E coli; D009601:Nitroreductases; D027101:DNA Topoisomerase IV